End-of-day quote
Other stock markets
|
||
- HKD | - |
|
Jul. 16 | Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating | MT |
Jul. 16 | Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 1,416 | 100.0 % | 2,459 | 100.0 % | +73.65% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
45.9
%
| 503 | 35.5 % | 1,128 | 45.9 % | +124.46% |
China
44.8
%
| 840 | 59.3 % | 1,102 | 44.8 % | +31.18% |
Europe
8.2
%
| - | - | 202 | 8.2 % | - |
Rest of World
1.1
%
| 73 | 5.2 % | 27 | 1.1 % | -63.70% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,244,457,968 | 1,222,239,074 ( 98.21 %) | 0 | 98.21 % |
Company contact information
![address Beigene Ltd](https://cdn.zonebourse.com/static/address/46178119.png)
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+18.54% | 126B | |
+23.08% | 118B | |
+23.26% | 27.87B | |
-18.51% | 20.95B | |
-15.13% | 16.92B | |
+9.48% | 14.84B | |
-46.10% | 14.79B | |
+52.19% | 14.08B | |
+143.01% | 12.57B |
- Stock Market
- Equities
- BGNE Stock
- Stock
- Company Beigene Ltd